Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: An overview of its pharmacological and clinical characteristics

American Journal of Hospice and Palliative Medicine

Volumn 22, Issue 3, 2005, Pages 228-232

  Mystakidou, Kyriaki ^a   Katsouda, Emmanuela ^a   Parpa, Efi ^a   Tsiatas, Marinos L ^a   Vlahos, Lambros ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breakthrough pain; Cancer; Oral transmucosal fentanyl citrate

Indexed keywords

FENTANYL CITRATE; HYDROMORPHONE; MORPHINE; MORPHINE SULFATE; OPIATE; OXYCODONE;

ANALGESIA; ANESTHESIA; ASTHENIA; BRADYCARDIA; CANCER PAIN; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIAPHORESIS; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; EUPHORIA; FIRST PASS EFFECT; FLUSHING; GASTROINTESTINAL TRACT; HUMAN; HYPOVENTILATION; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TOXICITY; VOMITING;

EID: 19744366577     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910502200313     Document Type: Review

References (21)

1. Portenoy RK, Hagen NA: Breakthrough pain: Definition, prevalence, and characteristics. Pain. 1990; 41(3): 273-281.
2. Portenoy RK, Payne R, Coluzzi P, et al.: Oral transmucosal fentanyl citrate (ACTIQ) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain. 1999; 79: 303-312.
3. Simmonds MA: Management of breakthrough pain due to cancer. Oncology. 1999; 13(8): 1103-1108.
4. McMenamin E, Farrar JT: Oral transmucosal fentanyl citrate: A novel agent for breakthrough pain related to cancer. Expert Rev Anticancer Ther. 2002; 2(5): 625-629.
5. Portenoy RK, Southam MA, Gupta SK, et al.: Transdermal fentanyl for cancer pain: Repeated dose pharmacokinetics. Anesthesiology. 1993; 78(1): 36-43.
6. Cephalon, Inc.: Actiq®: Summary of Product Characteristics. Salt Lake City, UT: Cephalon, Inc., January 2003.
7. Mather LE: Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 1983; 8(5): 422-446.
8. Meuldermans WEG, Hurkmans RMA, Heykants JJP: Plasma protein binding and distribution of fentanyl, sufentanil, afentanil, and lofentanil in blood. Arch Int Pharmacodyn Ther. 1982; 257(1): 4-19.
9. Tamsen A, Sakurada T, Wahlstrom A, et al.: Postoperative demand for analgesics in relation to individual levels of endorphins and substance P in cerebrospinal fluid. Pain. 1982; 13(2): 171-183.
10. Cohen MR, Pickar D, Dubois M, et al.: Stress-induced plasma beta-endorphin immunoreactivity may predict postoperative morphine usage. Psychiatry Res. 1982; 6(1): 7-12.
11. Cartwright P, Prys-Roberts C, Gill K, et al.: Ventilatory depression related to plasma fentanyl concentrations during and after anesthesia in humans. Anesth Analg. 1983; 62(11): 966-974.
12. Streisand JB, Varvel JR, Stanski DR, et al.: Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology. 1991; 75(2): 223-229.
13. Streisand JB, Busch MA, Egan TD, et al.: Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology. 1998; 88(2): 305-309.
14. Lee M, Kern SE, Kisicki JC, et al.: A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage. 2003; 26(2): 743-747.
15. Poklis A: Fentanyl: A review for clinical and analytical toxicologists. J Toxicol Clin Toxicol. 1995; 33(5): 439-447.
16. Mystakidou K: E-TRANS fentanyl. ALZA. Curr Opin Investig Drugs. 2002; 3(3): 463-469.
17. Christie JM, Simmonds M, Patt R, et al.: Dose titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998; 16(10): 3238-3245.
18. Farrar JT, Cleary J, Rauck R, et al.: Oral transmucosal fentanyl citrate: Randomised, double-blinded, placebo-controlled trial for the treatment of breakthrough pain in cancer patients. J Nat Cancer Institute. 1998; 90(8): 611-616.
19. Coluzzi PH, Schwartzberg L, Conroy Jr. JD, et al: Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001; 91(1-2): 123-130.
20. Payne R, Coluzzi P, Hart L, et al.: Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage. 2001;22(1): 575-583.
21. Burton AW, Driver LC, Mendoza TR, et al.: Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: A retrospective case series. Clin J Pain. 2004; 20(3): 195-197.